Can scans replace breathing tests to monitor lung scarring?
NCT ID NCT05492994
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study follows 31 people with progressive fibrosing interstitial lung disease (PF-ILD) for one year. Researchers compare imaging scans (CT and MRI) with standard breathing tests to see which method best tracks lung damage over time. The goal is to find better ways to measure disease progression for use in future drug trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help develop better imaging tools to monitor lung disease progression and improve future clinical trials.
- What could go wrong
- This is a small observational study, not a treatment trial. The imaging methods may not prove more useful than standard lung function tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medizinische Hochschule Hannover
Hanover, 30625, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care